US tax revenues as a percentage of GDP have been fairly stable over the long term (IIRC), so if government’s a problem it’s not in the sense of government capturing all the resources. Regulation could be an issue.
The most recent big innovation in energy is fracking. Clearly this has experienced regulatory headwinds, and a pile of environmentalists are looking for rationalizations to stop it, but on the whole, looks to me like a reasonable rate of innovation in energy, which is in substantial part compensating for the exhaustion of hydrocarbon resources. Doubtless we could do better, but it is not obvious that to me that energy innovation is slower than would reasonably be expected in a mature field.
A good measure of innovation is new therapeutic molecular entities, because one can simply count them. By that measure, innovation in the west and Japan has slowed down drastically and alarmingly, though China and Taiwan are speeding up.
I observe ads by Singapore promising a more favorable regulatory environment for drug development. They don’t have a drug research industry and are hoping for one. This suggests the existence of an unfavorable regulatory environment for drug development. It is clear that western development of new therapeutic molecular entities has slowed alarmingly.
US tax revenues as a percentage of GDP have been fairly stable over the long term (IIRC), so if government’s a problem it’s not in the sense of government capturing all the resources. Regulation could be an issue.
The most recent big innovation in energy is fracking. Clearly this has experienced regulatory headwinds, and a pile of environmentalists are looking for rationalizations to stop it, but on the whole, looks to me like a reasonable rate of innovation in energy, which is in substantial part compensating for the exhaustion of hydrocarbon resources. Doubtless we could do better, but it is not obvious that to me that energy innovation is slower than would reasonably be expected in a mature field.
A good measure of innovation is new therapeutic molecular entities, because one can simply count them. By that measure, innovation in the west and Japan has slowed down drastically and alarmingly, though China and Taiwan are speeding up.
I observe ads by Singapore promising a more favorable regulatory environment for drug development. They don’t have a drug research industry and are hoping for one. This suggests the existence of an unfavorable regulatory environment for drug development. It is clear that western development of new therapeutic molecular entities has slowed alarmingly.